Compugen SVP exercises options, sells 3,125 shares

Compugen Ltd. senior vice president Zurit Levine exercised share options and sold shares in a planned transaction.

Rhea-AI Filing Summary

Compugen Ltd. senior vice president Zurit Levine exercised share options and sold shares in a planned transaction. On April 10, 2026, she exercised options for a total of 3,125 Ordinary Shares at strike prices of $0.8292 and $1.15 per share, then sold 3,125 Ordinary Shares at a weighted average price of $2.564 per share under a Rule 10b5-1 trading plan. Following these transactions, she holds 29,375 Ordinary Shares directly and retains share option positions totaling 5,625 and 56,000 options, respectively.

Insider Trade Summary 10b5-1

Exercise and Sale: 3,125 shares ($5K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Levine Zurit

Role SVP, Business Development

Sold 3,125 shs ($8K)

Approx. gross sale proceeds $8K

Approx. exercise cost $3K

Approx. pre-tax spread $5K

Type	Security	Shares	Price	Value
Exercise	Share Option (right to buy)	1,125	$0.00	$0.00
Exercise	Share Option (right to buy)	2,000	$0.00	$0.00
Exercise	Ordinary Shares	1,125	$0.8292	$932.85
Exercise	Ordinary Shares	2,000	$1.15	$2K
Sale	Ordinary Shares	3,125	$2.564	$8K

Holdings After Transaction: Share Option (right to buy) — 61,625 contracts (Direct); Ordinary Shares — 29,375 shares (Direct)

Footnotes (4)

1. F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
4. F4. This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Shares sold: 3,125 shares Sale price: $2.564/share Options exercised: 3,125 shares +3 more

6 metrics

Shares sold 3,125 shares Ordinary Shares sold at weighted average $2.564 on April 10, 2026

Sale price $2.564/share Weighted average sale price; individual trades $2.50–$2.60

Options exercised 3,125 shares Ordinary Shares from option exercises at $0.8292 and $1.15

Post-transaction holdings 29,375 shares Ordinary Shares held directly after April 10, 2026 transactions

Remaining option grant 1 5,625 options Share Option (right to buy) expiring November 9, 2032

Remaining option grant 2 56,000 options Share Option (right to buy) expiring August 3, 2033

Key Terms

Rule 10b5-1 trading plan, Share Option (right to buy), weighted average price, Ordinary Shares, +1 more

5 terms

Rule 10b5-1 trading plan financial

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Share Option (right to buy) financial

"security_title: "Share Option (right to buy)""

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Compugen (CGEN) SVP Zurit Levine report?

Zurit Levine reported exercising options for 3,125 Ordinary Shares and selling 3,125 Ordinary Shares. The transactions combined an option exercise with an open-market sale executed under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025.

At what prices did the Compugen (CGEN) SVP exercise and sell shares?

Levine exercised options at strike prices of $0.8292 and $1.15 per share and sold 3,125 Ordinary Shares at a weighted average price of $2.564, with individual sale prices ranging from $2.50 to $2.60 per share, according to the disclosure.

How many Compugen (CGEN) shares does Zurit Levine hold after these transactions?

After the reported transactions, Levine directly holds 29,375 Ordinary Shares of Compugen. She also continues to hold share options, with post-transaction option balances of 5,625 and 56,000 underlying Ordinary Shares on two separate option awards.

Were the Compugen (CGEN) insider sales by Zurit Levine pre-planned?

Yes. The filing states the sale was made under a Rule 10b5-1 trading plan adopted on December 23, 2025. Such plans allow insiders to schedule trades in advance, helping separate trading decisions from later nonpublic information.

What type of securities did Compugen (CGEN) SVP Zurit Levine exercise?

Levine exercised “Share Option (right to buy)” awards that convert into Ordinary Shares. One option grant carries an exercise price of $0.8292 and another carries an exercise price of $1.15, both with multi-year vesting and long-dated expiration schedules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/13/2026 - 04:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levine Zurit

(Last) (First) (Middle)

C/O COMPUGEN LTD.

26 HAROKMIM STREET

(Street)

HOLON 5885849

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
COMPUGEN LTD [ CGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Business Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/10/2026		M(1)		1,125	A	$0.8292	30,500	D
Ordinary Shares	04/10/2026		M(1)		2,000	A	$1.15	32,500	D
Ordinary Shares	04/10/2026		S(1)		3,125	D	$2.564(2)	29,375	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$0.8292	04/10/2026		M(1)			1,125	(3)	11/09/2032	Ordinary Shares	1,125	$0	5,625	D
Share Option (right to buy)	$1.15	04/10/2026		M(1)			2,000	(4)	08/03/2033	Ordinary Shares	2,000	$0	56,000	D

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

4. This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

	/s/ Zurit Levine	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)